MANGOCEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
MGRX$0.19-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
| For The | For The | For The | For The | |
|---|---|---|---|---|
| Three Months Ended | Three Months Ended | Six Months Ended | Six Months Ended | |
| June 30, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | |
| Net loss attributable to Mangoceuticals, Inc. | $(2,391,319) | $(2,284,025) | $(4,758,936) | $(4,844,910) |
| Other comprehensive expense | ||||
| Foreign currency adjustments | (1,096) | - | (1,166) | - |
| Comprehensive loss | (2,392,415) | (2,284,025) | (4,760,102) | (4,844,910) |
| Other comprehensive expense | ||||
| Net loss attributed to non-controlling interest | (340) | - | (376) | - |
| Comprehensive loss attributable to Mangoceuticals, Inc. | (2,392,075) | (2,284,025) | (4,759,726) | (4,844,910) |
MANGOCEUTICALS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.